{"brief_title": "A Study of Disease Progression and Anti-HIV Treatments", "brief_summary": "To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Lamivudine"], "criteria": "Inclusion Criteria Patients must have: - Prior participation on protocol ACTG 175. PER AMENDMENT 8/27/96: - Patients must be on study/on treatment at the time the protocol study treatment is extended.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Lamivudine", "mesh_term": ["HIV Infections", "Disease Progression", "Lamivudine"], "id": "NCT00001068"}